All early stage biotechs lose money, often substantial amounts, before crossing the chasm to achieve profitability. Also, it is expensive to do clinical trials for direct human therapy which is why Ruthigen is being spun out, to raise funds to do clinical trials for human applications. This is all consistent with early stage biotech ventures. The progress is what counts and that has been dramatic and impressive. The key metrics are growth in sales, market potential and new market approvals/agreements, licenses to marketing partners...to name a few. If we add profitability to the metrics that would make a strong combination for investor value creation.
Companies, markets and national regulatory agencies do not grant approvals without cause and OCLS has a long string of documented approvals in a growing list of markets. Instead of a forum post by one individual bashing the product, I'd rather accept the endorsement of regulatory agencies in many countries that have approved this product and technology.
Cool. Sounds like a similar strategy. I have bought CSTR several times in the past 2 years on weakness and sold on strength, currently on the sidelines but always watching for a buy signal - only thing I don't like right now is the proposed name change (Outer Wall?).
For my penny stock, I am only holding OCLS right now thinking there may be a market correction this summer but that's just my personal opinion, no technical reasons esp. with oil and natgas so low (high oil is a market crash indicator). Also, there are so many foreign economies in the dumpster which forces them to invest in U.S. stocks. So I am on the sidelines right now except for OCLS which I am buying on weakness. Interesting to share stock strategies and choices, just to compare.
Baystreet has a new article on Investment Ideas in the Expanding Wound Care Market that briefly mentions Oculus. The article says this is a $27 billion market although only a handful of companies are active in this market. The market opportunity is enormous and Oculus is well positioned and gaining ground every day. The article also mentions that clinical trials should expand the market with new human apps.
Today I acquired more shares in OCLS. My strategy is very simple. At this point in the company's history - which has been admittedly rocky and bumpy - I am accumulating shares on weakness and as an investor I am looking at a 2 year+ time horizon and this suggests the current valuation is low and if the stock drops lower I plan to accumulate more. I think this is a terrific investment in a company that has struggled and is finally poised to make a breakout in the market with a product that is obviously needed, globally. I see applications in places where antibiotic resistant strains are emerging, and where inexpensive non-antibiotic solutions are needed which includes emerging markets in many countries. The human trials open another market area and the promise of this sector remains to be seen but it sounds very promising. I also feel that the market cap of the company suggests the possibility that OCLS could be an acquisition target in the future by a large corporation that has global market access and could boost sales through better distribution. This is my own personal feeling about the company, as an investor, and why I am positive on OCLS.
Sentiment: Strong Buy
Very nice explanation - and much appreciated. The phrase that is most relevant is: "There is no other stable bottled hypochlorous acid product available." Thank you for this thoughtful technical summary that explains why Microcyn is obtaining so many new licenses globally, and also explains the potential and importance of the clinical trials planned for human use apps (with the Ruthigen IPO providing funding for the clinical trials).
I've been out of CSTR since cashing out last down-up cycle, and haven't visited this board much but I'm disappointed to see that the spam clutter is still plaguing this board, while I don't seem to find this nonsense on other boards. My most recent trade was ABBV which I bought at $43+ and sold at $46+ and I also hold OCLS as my "penny stock" - I always own one long term high risk penny stock in my portfolio. I'm currently watching CSTR to see if it drops closer to $50 or lower on a market correction. Hope everyone is making $$.
Not desperate, just frustrated when I tried to buy shares at the posted price yesterday. Actually hoping it goes lower to accumulate. My time horizon is 2 years so I'm fine with ups and downs.
If you're so down on the stock, sell me a few thou shares at this price, okay?
The price on OCLS dropped unexpectedly on no news and no rumors - plus - there seemed to be a lot of very small trades but no big sellers. This suggests that maybe some investors were selling to each other at increasingly low prices, driving down the prices - and also explains why no one could buy any sizable amounts, because those who own the stock have no reason to sell at these prices because OCLS is going to return to $5.50-$6.00 this year so no reason to sell. I tried to add to my holdings but couldn't get anyone to sell at these low levels, so that confirms my premise. I hope no one got psyched out by what appears to be an artificially engineered price/volume maneuver.
This sums it up. If we looked at the rough periods at Apple, Netflix, Ford and many other stocks/companies, we would never invest in these and others. OCLS had a rough startup phase, which is true, but now they are poised for growth and stability and moving steadily from startup losses toward profitability. Their market is enormous, and they are signing up new regions and receiving foreign market approvals as fast as they can negotiate them. Their products are on the shelves of thousands of hospitals and clinics and this speaks for itself. Long investors have to keep looking forward. What I learned from the past is that OCLS has emerged from a rough startup period to a very strong basis for growth and if you lost money in the early stages, it's probably a bitter pill to see the company finding its footing and gaining traction, but that's reality and investors now are profiting. As I've said before, this was my only penny stock when I started and now it's becoming a very promising investment which is very very cool.
Sentiment: Strong Buy
Actually, I have doubled my long position instead of a 30% increase mentioned in the May 8 post, taking advantage of the recent decline. Based on fundamentals and future prospects, I think this is a good long-term (1-2 year) investment.
Sentiment: Strong Buy
There is a constant flow of news these days. The IPO could be on target or delayed, depending on the investment climate, but since they want to get started I don't see how they would delay it - also, they had some success in their financing and dilution rounds, so they seem to be well connected for funding. I've made two purchases at or near the recent bottom and am very happy to be accumulating more shares on weakness, coming I guess from the recent so-called "analysis" article.
This may not show how few investors there are, but rather how many are holding the stock through this fake hit job, instead of selling off. Most investors are in this for a longer term and patiently waiting for Ruthigen, clinical trials, future profitability, more global expansion...all LONG TERM fundamentals, which require patience and staying power. That means that some speculators can move the stock up or down with very little effort, but it also means that a lot of people aren't going to be swayed by a random article. Keep in mind that most of what anyone might consider "dirt" is already out there and nothing comes as a surprise at this point except upside potential which is looming in a 2 year time frame.
Seems that I accumulated more shares right at the bottom after the Seeking Alpha contributor slammed the stock. By the way, his points were that: 1) the CEO is making too much money (hey...ALL CEOs are overpaid!); 2) institutions show no interest (that's false, 24 institutions own the stock); and 3) several years ago a licensee misrepresented their product - that's really old stuff. The biggest negative is the money lost by early investors who bought in too soon before the company found its footing. It's one thing to invest too soon in a biotech and lose $$ but it's another to ignore the company when it finally starts to gain traction. The writer also says the IPO is the only thing driving the stock. Wrong. They beat the street by a few pennies, and are moving slowly, inevitably, toward sustainable profitability. Like any biotech, when they reach consistent profits, the company stock has the potential to fly. From my point of view, Ruthigen is just a nice bonus, not the main reason for investing - although doing a spinoff to fund and run clinical trials suggests that this company is moving toward the kind of medical apps that require clinical trials and that's a big deal.
OCLS was downgraded by Zacks from an "outperform" rating to a "neutral" rating in a research report issued to clients and investors on Wednesday, ARN reports. They have a $6.40 price target on the stock. Maxim Group raised their price target on shares of Oculus Innovative Sciences from $2.80 to $6.00 and have a "buy" rating on the stock.
I've profited from buying OCLS on weakness and increased my position by 30% today. Any short term hit will be overcome by future financials - my main analysis is that OCLS will be "consistently profitable" in 2014, so this for me is accumulation of shares in anticipation. I don't care if shorts sell or cover or whatever, this month or this summer. My horizon is 18 months out.
AbbVie's Investigational HCV Regimen has received Breakthrough Therapy Designation by the FDA. As an investor, I view this as a critical and very positive announcement considering that the company's future after Humira expires in 2016 will rely in part on the progress of their Hepatitis C drugs. Also, ABBV is presenting next week at a BofA analyst conference so there may be more info of interest to investors presented there.